Literature DB >> 16425400

Association of Helicobacter pylori IgA antibodies with the risk of peptic ulcer disease and gastric cancer.

Timo U Kosunen1, Kari Seppala, Seppo Sarna, Arpo Aromaa, Paul Knekt, Jarmo Virtamo, Anniina Salomaa-Rasanen, Hilpi Rautelin.   

Abstract

AIM: To compare the prevalence of Helicobacter pylori (H pylori) IgG and IgA antibodies between adult subjects, with defined gastric diseases, non-defined gastric disorders and those representing the population.
METHODS: Data on H pylori IgG and IgA antibodies, determined by enzyme immunoassay, were analyzed in 3,252 subjects with DGD including 482 patients with gastric ulcer, 882 patients with duodenal ulcer, 1,525 patients with chronic gastritis only and 363 subjects with subsequent gastric cancer, 19,145 patients with NoDg and 4,854 POPUL subjects. The age-adjusted prevalences were calculated for 1- and 20-year age cohorts.
RESULTS: The prevalences of IgG antibodies were equally high (89-96%) in all 20-year age cohorts of the DGD groups, whereas the prevalences of IgG antibodies were lower and increased by age in the POPUL and NoDg groups. The prevalences of IgA antibodies were also higher in the DGD groups; among them CA (84-89%) and GU groups (78-91%) showed significantly higher prevalences than DU (68-77%) and CG patients (59-74%) (OR 2.49, 95%CI 1.86-3.34 between the GU and DU groups). In the CA, GU, and DU groups, the IgA prevalences showed only minor variation according to age, while they increased by age in the CG, POPUL, and NoDg groups (P<=0.0001). The IgA response, but not the IgG response, was associated with an increased risk of CA (OR 2.41, 95%CI 1.79-3.53) and GU (OR 2.57, 95%CI 1.95-3.39) in comparison with CG patients.
CONCLUSION: An IgA antibody response during H pylori infection is significantly more common in CA and GU patients as compared with CG patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425400      PMCID: PMC4725036          DOI: 10.3748/wjg.v11.i43.6871

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Association of CagA-positive infection with Helicobacter pylori antibodies of IgA class.

Authors:  H I Rautelin; A M Oksanen; R A Karttunen; K M Seppälä; J R Virtamo; A J Aromaa; T U Kosunen
Journal:  Ann Med       Date:  2000-12       Impact factor: 4.709

Review 2.  Helicobacter pylori.

Authors:  B J Marshall
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

3.  Evaluation of Pyloriset Screen, a rapid whole-blood diagnostic test for Helicobacter pylori infection.

Authors:  A Oksanen; L Veijola; P Sipponen; K O Schauman; H Rautelin
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

Review 4.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts.

Authors: 
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

5.  Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori.

Authors:  T U Kosunen; K Seppälä; S Sarna; P Sipponen
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

6.  Gastric precancerous process in a high risk population: cohort follow-up.

Authors:  P Correa; W Haenszel; C Cuello; D Zavala; E Fontham; G Zarama; S Tannenbaum; T Collazos; B Ruiz
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

7.  Serologic detection of infection with cagA+ Helicobacter pylori strains.

Authors:  T L Cover; Y Glupczynski; A P Lage; A Burette; M K Tummuru; G I Perez-Perez; M J Blaser
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

8.  Age-dependent increase of Campylobacter pylori antibodies in blood donors.

Authors:  T U Kosunen; J Höök; H I Rautelin; G Myllylä
Journal:  Scand J Gastroenterol       Date:  1989-01       Impact factor: 2.423

9.  Seroprevalence of immunoglobulin G, M, and A antibodies to Helicobacter pylori in an unselected Danish population.

Authors:  L P Andersen; S J Rosenstock; O Bonnevie; T Jørgensen
Journal:  Am J Epidemiol       Date:  1996-06-01       Impact factor: 4.897

10.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

Authors:  E A Rauws; G N Tytgat
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

View more
  6 in total

Review 1.  Diet, H pylori infection and gastric cancer: evidence and controversies.

Authors:  Alba Rocco; Gerardo Nardone
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

2.  Antibodies as biomarkers for cancer risk: a systematic review.

Authors:  Maria J Monroy-Iglesias; Silvia Crescioli; Kerri Beckmann; Nga Le; Sophia N Karagiannis; Mieke Van Hemelrijck; Aida Santaolalla
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

3.  Myeloid-derived suppressor cells promote B-cell production of IgA in a TNFR2-dependent manner.

Authors:  Xia Xu; Qinghong Meng; Ulrike Erben; Peigang Wang; Rainer Glauben; Anja A Kühl; Hao Wu; Chung Wah Ma; Minghua Hu; Yuanyuan Wang; Wei Sun; Junying Jia; Xinyi Wu; Wei Chen; Britta Siegmund; Zhihai Qin
Journal:  Cell Mol Immunol       Date:  2016-05-02       Impact factor: 11.530

4.  Correlation of serum anti-helicobacter pylori immunoglobulin a (IgA) with histological parameters of chronic gastritis in ibadan, Nigeria.

Authors:  Ao Oluwasola; Ja Otegbayo; So Ola; Ho Ebili; Ao Afolabi; Gn Odaibo
Journal:  Ann Ib Postgrad Med       Date:  2012-06

5.  Gastric cancer progression associated with local humoral immune responses.

Authors:  López-Vidal Yolanda; Ponce-de-León Sergio; Esquivel-Solís Hugo; Amieva-Fernández Rosa Isabel; Barreto-Zúñiga Rafael; Torre-Delgadillo Aldo; Castillo-Rojas Gonzalo
Journal:  BMC Cancer       Date:  2015-11-21       Impact factor: 4.430

6.  Previous Exposure to the Fish Parasite Anisakis as a Potential Risk Factor for Gastric or Colon Adenocarcinoma.

Authors:  Juan Carlos Garcia-Perez; Rosa Rodríguez-Perez; Araceli Ballestero; Jaime Zuloaga; Belen Fernandez-Puntero; Javier Arias-Díaz; María Luisa Caballero
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.